Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 4/2007

01-04-2007 | Original Research Article

Insulin Detemir Results in Less Weight Gain than NPH Insulin When Used in Basal-Bolus Therapy for Type 2 Diabetes Mellitus, and this Advantage Increases with Baseline Body Mass Index

Authors: Dr Katarina Rašlová, Soren Can Tamer, Per Clauson, Diane Karl

Published in: Clinical Drug Investigation | Issue 4/2007

Login to get access

Abstract

Objective: Weight gain during insulin therapy can be a challenging problem in already overweight type 2 diabetes mellitus patients, affecting treatment compliance and long-term prognosis. The analogue insulin detemir has been reported to have a weight-sparing effect compared with other basal insulins. This pooled analysis investigated whether this potential advantage is related to body mass index (BMI) when insulin detemir is used as the basal component of basal-bolus therapy.
Methods: Data were pooled from two randomised, parallel group trials of 22 and 24 weeks’ duration, in which 900 insulin-treated patients with type 2 diabetes mellitus had their treatment intensified to basal-bolus therapy. Patients received once- or twice-daily insulin detemir or neutral protamine Hagedorn (NPH) insulin in conjunction with insulin aspart or human soluble insulin at mealtimes.
Results: Patients treated with insulin detemir had minimal weight gain (mean <1kg), regardless of their BMI at entry (estimated slope −0.032), whereas, in patients treated with NPH insulin, weight gain increased as baseline BMI increased (estimated slope 0.075, p = 0.025). Indeed, NPH insulin-treated patients with the largest BMI (>35 kg/m2) gained the most weight (mean of ∼2.4kg). In contrast, insulin detemir-treated patients with a BMI >35 kg/m2 lost weight (mean of ∼−0.5kg). Glycaemic control was similar with the two treatments.
Conclusion: Insulin detemir may provide a clinical advantage in terms of reduced weight gain in the treatment of overweight patients with type 2 diabetes.
Literature
1.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258): 405-12
2.
Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998; 158(2): 134–40PubMedCrossRef
3.
Weight gain associated with intensive therapy in the diabetes control and complications trial: the DCCT Research Group. Diabetes Care 1988; 11 (7): 567-73
4.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1999; 354 (9178): 602]. Lancet 1998; 352 (9131): 837-53
5.
Purnell JQ, Hokanson JE, Marcovina SM, et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT (Diabetes Control and Complications Trial). JAMA 1998; 290: 140–6CrossRef
6.
Ridderstrale M, Gudbjornsdottir S, Eliasson B, et al. Steering Committee of the Swedish National Diabetes Register (NDR). Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med 2006; 259(3): 314–22PubMedCrossRef
7.
Pieber TR, Draeger E, Kristensen A, et al. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005; 22(7): 850–7PubMedCrossRef
8.
De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7(1): 73–82PubMedCrossRef
9.
Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47(4): 622–9PubMedCrossRef
10.
Home P, Bartley P, Russell-Jones D, et al. Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) study group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004; 27(5): 1081–7PubMedCrossRef
11.
Russell-Jones D, Simpson R, Hylleberg B, et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26(5): 724–36PubMedCrossRef
12.
Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004; 6(5): 579–88PubMedCrossRef
13.
Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26(3): 590–6PubMedCrossRef
14.
Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomised, parallel treat-to-target trial comparing efficacy and tolerability of insulin detemir versus NPH insulin as addon therapy to OADs in subjects with type 2 diabetes. Diabetes Care 2006; 29(6): 1269–74PubMedCrossRef
15.
Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7(1): 56–64PubMedCrossRef
16.
Raslova K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes [published erratum appears in Diabetes Res Clin Pract 2006; 72 (1): 112]. Diabetes Res Clin Pract 2004; 66(2): 193–201PubMedCrossRef
17.
Fritsche A, Haring H. At last, a weight neutral insulin? Int J Obes 2004; 28Suppl. 2: S41–6CrossRef
18.
Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 2006; 7(3): 325–43PubMedCrossRef
19.
Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53(6): 1614–20PubMedCrossRef
20.
Kolendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med 2006; 23(7): 729–35PubMedCrossRef
21.
Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26(11): 3080–6PubMedCrossRef
22.
Hordern SV, Wright JE, Umpleby AM, et al. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 2005; 48(3): 420–6PubMedCrossRef
23.
24.
Hennige AM, Sartorius T, Tschritter O, et al. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006; 49(6): 1274–82PubMedCrossRef
25.
Tschritter O, Porubska K, Hennige A, et al. Neuronal activation of the human cerebral cortex by administration of insulin detemir compared to human insulin [abstract]. Diabetologia 2005; 48Suppl. 1: A256
Metadata
Title
Insulin Detemir Results in Less Weight Gain than NPH Insulin When Used in Basal-Bolus Therapy for Type 2 Diabetes Mellitus, and this Advantage Increases with Baseline Body Mass Index
Authors
Dr Katarina Rašlová
Soren Can Tamer
Per Clauson
Diane Karl
Publication date
01-04-2007
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 4/2007
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200727040-00007

Other articles of this Issue 4/2007

Clinical Drug Investigation 4/2007 Go to the issue

Original Research Article

Relative Bioavailability, Metabolism and Tolerability of Rectally Administered Oxcarbazepine Suspension

Original Research Article

Pharmacoeconomic Analysis of Liposomal Amphotericin B versus Voriconazole for Empirical Treatment of Febrile Neutropenia

Original Research Article

Efficacy and Tolerability of Oxycodone Hydrochloride Controlled-Release Tablets in Moderate to Severe Cancer Pain

Original Research Article

Prevention of Osteoporosis

Original Research Article

Pantoprazole On-Demand Effectively Treats Symptoms in Patients with Gastro-Oesophageal Reflux Disease

Original Research Article

Effects of Esmolol, Lidocaine and Fentanyl on Haemodynamic Responses to Endotracheal Intubation